Next Generation Lipid-Based Nanoparticles Delivery Summit
Unlocking the Potential of Lipid-Based Nanoparticles by
Engineering the Best-in-Class, ‘Self-Guided’ Vehicle
We Are Live For Day Two!
Harness Safe & Efficacious Lipid-Based Delivery for Novel Therapeutics Beyond RNA & Hepatic Tissue
The recent success of the mRNA-LNP vaccines fueled biopharma to explore lipid-based nanoparticles for advanced drug delivery. The industry is now poised to exploit the full therapeutic potential of these vehicles for emerging payloads and extrahepatic delivery.
The Next Generation Lipid-Based Nanoparticles Delivery Summit is your definitive industry-led meeting to design and engineer 2nd generation of lipid nanoparticles for emerging payloads beyond RNA into clinic. Join Intellia Therapeutics, Entos Pharmaceuticals, AstraZeneca, Eli Lilly, and other scientific trailblazers as they navigate the next generation of lipid-based nanoparticles for targeted delivery to expedite innovative treatments for unmet patient needs.
Over 3 days, we:
Explored translating novel lipid chemistry and design – reviewing the journey from liposomes to LNP, from synthetic LNPs to lipid nano-crystals – to maximize cytosolic delivery and minimize immunogenicity and toxicity
Unlocked the full potential of nanoparticles and assess lipid-based for new payloads – including CRISPR Cas9, DNA, cell & gene therapies, oligos and macromolecules
Improved the safety and efficacy of lipid-based delivery beyond RNA through formulation, particle engineering, and chemical design to overcome intracellular barriers
2022 World-Class Speaker Faculty
Senior Director & Head of LNP Discovery
Chief Technology & Manufacturing Officer
What Previous Attendees of our RNA Conference Series Have to Say:
“We are at the most exciting point in human history with respect to the launch and development of therapies. I am looking forward to hearing about the latest advances to safely and effectively target various tissues.”
Dominik Witzigmann, Co-Founder & Chief Executive Officer, Nanovation Therapeutics
“What I’m looking forward to is understating current trends in LNP formulations manufacturing and expansion of knowledge that can be integrated into value creation for a clinical-stage company.”
Hemant Kumar, Chief Technology & Manufacturing Officer, Genprex